The Chlamydia Infection Diagnostic & Therapeutic Market Size is estimated to reach $1.1 billion by 2027 and it is poised to grow at a CAGR of 6.1% over the forecast period of 2022-2027. Chlamydia is a common form of STD (Sexually Transmitted Disease) that can cause infection in both men and women. The Chlamydia Infection Diagnostic & Therapeutic Market Size is estimated to reach $1.1 billion by 2027 and it is poised to grow at a CAGR of 6.1% over the forecast period of 2022-2027. Chlamydia is a common form of STD (Sexually Transmitted Disease) that can cause infection in both men and women. Chlamydia can also cause a potentially fatal ectopic pregnancy (pregnancy that occurs outside the womb). Chlamydia can be diagnosed with nucleic acid amplification tests (NAATs), cell cultures and other types of tests. Chlamydia can usually be effectively treated with the right dosage of antibiotics such as macrolides, sulfonamides and tetracycline. Due to an increasing public-private infrastructure loomed by the government and foreign agencies, the market would find immense opportunities during the forecast period of 2022-2027. 

For More Queries About "Chlamydia Infection Diagnostic & Therapeutic Market"
@ https://www.industryarc.com/support.php?id=17459

Chlamydia Infection Diagnostic & Therapeutic Market Drivers

The Sustaining Prevalence of Chlamydia Across the Globe:

Chlamydia has historically been a highly prevalent form of STD within the US. As per the Sexually Transmitted Disease Surveillance report of 2020, chlamydia had nearly 1.6 million cases in 2020. CDC further adds that the overall incidence of this STD has reduced marginally. However, the overall impact of the disease remains extremely high in the category of STDs. The numbers for Chlamydia stand at nearly 250,000 cases in Europe as per the European Center for Disease Prevention and Control.

The Looming Support from Global Agencies along with Silent Epidemics in Under-developed Nations:

As per a 2020 WHO report, the agency plans to eradicate major STIs from the globe or reduce the total prevalence by nearly 90% of the current standards. Moreover, the major increase in the diagnostic and treatment of chlamydia across the globe has been a growth propeller. In the underdeveloped regions of Africa, such a form of epidemic looms at large, which, if corrected, would offer opportunities to marketers.

Research and Product Launch

In May 2022, Becton, Dickinson and Company announced the launch of its new, fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States. The initial test on the new system is a single test that detects the most prevalent non-viral STD such as chlamydia trachomatis. In September 2022, Chlamydia’s stealth cloaking device was identified by Duke University Researchers. As per the research, microbial proteins around the STD allow the pathogen to hide undetected inside the host cells.

The Major Players in the Market

The major players in the Chlamydia Infection Diagnostic & Therapeutic Market include Abbott Labs, Beckton-Dickinson Company, Bio-Rad Labs, Danaher Corporation, DiaSorin SpA, F. Hoffman Lo-Roche Ltd, Hologic Inc, Quidel Corporation, Savyon Diagnostics and Trinity Biotech.

To request for a quote, provide your details in the below link:

Media Contact:

Mr. Venkat Reddy
Sales Manager
Email: [email protected]
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.